CAMBRIDGE, Mass., Jan. 8 /PRNewswire/ -- Satori Pharmaceuticals Incorporated, a privately held developer of therapeutics for Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders, today announced $22 million in institutional financing.